Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Alpharadin

- PMLiVE

AbbVie expects Humira to drive growth in inaugural guidance

First statement since split from Abbott

- PMLiVE

Bayer’s Diane 35 faces ban in France

Follows investigation into blood clot-related deaths

Roche - Basel

Roche delivers solid sales gain in 2012

New cancer products, such as Perjeta and Zelboraf, help growth

- PMLiVE

New products help Lilly achieve flat Q4 sales

Effient and Alimta counter patent expiry to Zyprexa

- PMLiVE

Pfizer revenues decline in Q4 but profits surge

Lipitor patent loss continues to hit sales

- PMLiVE

EMA starts contraceptive safety probe

Follows French investigation into Bayer’s Diane 35

- PMLiVE

Biogen Idec posts solid Q4 results and says more to come

MS drugs Tysabri and Avonex lift sales

- PMLiVE

France investigates Bayer’s acne drug Diane 35 after deaths

Linked to blood clots in women

Bristol-Myers Squibb (BMS) building

BMS Q4 results see earnings increase despite fall in sales

Cost-cutting measures at pharma company help overcome patent losses

- PMLiVE

Amgen profits down on rising costs

R&D and general operating expenses cancel out rise in product sales

Novartis building

Novartis expects tough 2013 before a return to growth

Says it will take a year for new medicine sales to overcome Diovan patent loss

- PMLiVE

J&J sales rise but miss analysts’ targets in Q4

Leads in number of FDA approvals since 2009

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links